154 patents
Page 7 of 8
Utility
Medroxyprogesterone Acetate Injectable Compositions and Methods of Use
9 Sep 20
The disclosure is directed to medroxyprogesterone compositions suitable for subcutaneous injection comprising about 360 mg/ml to 440 mg/ml or about 160 mg/ml to 240 mg/ml medroxyprogesterone acetate, 1.2 mg/ml to 3.0 mg/ml docusate sodium, polyethylene glycol, and water.
Prakash SUNDARAMURTHI, Ivana MIJAKOVAC
Filed: 6 Sep 18
Utility
Solid State Forms of Elafibranor
9 Sep 20
Disclosed are solid state forms of Elafibranor and salts thereof, processes for preparation thereof and pharmaceutical compositions thereof.
Ivana LANDEKA, Dijana Skalec SAMEC
Filed: 15 Nov 18
Utility
Solid State Forms of Trisodium Valsartan: Sacubitril
2 Sep 20
Solid state forms of trisodium valsartan:sacubitril, processes for their preparation, pharmaceutical compositions containing such solid state forms and treatment methods using the pharmaceutical compositions are described.
Edislav Leksic, Dijana Skalec Samec, Damir Sahnic, Dejan Kisicek, Martina Hrkovac, Edi Topic
Filed: 19 May 20
Utility
Process for preparing quinolin-2-yl-phenylamine derivatives and their salts
17 Aug 20
Sebastian Rabe, Wolfgang Albrecht
Filed: 31 Oct 19
Utility
Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same
5 Aug 20
The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody.
Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
Filed: 16 Sep 19
Utility
New Crystalline Polymorphs of Bardoxolone Methyl
15 Jul 20
Disclosed are crystalline polymorphs of Bardoxolone methyl, and pharmaceutical compositions thereof.
Ivana LANDEKA, Helena CERIC
Filed: 11 Jul 18
Utility
Treating Refractory Migraine
15 Jul 20
Disclosed herein are methods of treating or reducing incidence of migraine and/or at least one secondary symptom associated with refractory migraine in a subject having refractory migraine comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway.
Marcelo Bigal, Ernesto Aycardi
Filed: 10 Jul 19
Utility
New Crystalline Polymorph of Ponesimod
8 Jul 20
The present disclosure encompasses crystalline polymorphs of Ponesimod, processes for preparation thereof, and pharmaceutical compositions thereof.
Sundara Lakshmi Kanniah, Kanhaiyalal, Anantha Rajmohan Muthusamy
Filed: 6 Sep 18
Utility
Solid State Forms of Entrectinib
8 Jul 20
The present disclosure relates to solid state forms of Entrectinib, processes for the preparation thereof, pharmaceutical formulations/compositions thereof, and methods of use thereof.
Sanja Matecic Musanic
Filed: 7 Jan 20
Utility
Use of Rasagiline for the Treatment of Restless Legs Syndrome
1 Jul 20
Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.
Eran Blaugrund, Ruth Levy
Filed: 10 Mar 20
Utility
Solid state forms of trisodium valsartan: sacubitril
22 Jun 20
Solid state forms of trisodium vaisartan:sacubitril, processes for their preparation, pharmaceutical compositions containing such solid state forms and treatment methods using the pharmaceutical compositions are described.
Edislav Leksic, Dijana Skalec Samec, Damir Sahnic, Dejan Kisicek, Martina Hrkovac, Edi Topic
Filed: 9 Jun 16
Utility
Solid State Forms of Ixazomib Citrate
17 Jun 20
The present disclosure encompasses solid state forms of Ixazomib Citrate and pharmaceutical compositions thereof.
Martin VALIK, Roman GABRIEL, Pavel VRASPIR, David LUKAS
Filed: 25 Feb 20
Utility
Processes for the Preparation of Niraparib and Intermediates Thereof
17 Jun 20
The present invention relates to novel procedures and novel intermediates useful in the synthesis of Niraparib or any salt thereof.
Parven K. Luthra, Sanjay L. Vasoya, Bhatu T. Patil, Amit K. Taneja, Naveen C. Srivastav, Rinku Singh
Filed: 13 Aug 18
Utility
Processes for the preparation of sofosbuvir and intermediates thereof
8 Jun 20
Vinod Kumar Kansal, Dhirenkumar Natvarial Mistry, Srinivas Achanta, Sundaraselvan Ariyamuthu, Miteshgir Kanchangir Goswami, Venkata Subbarao Yazali
Filed: 1 Jun 16
Utility
Methods of preparing co-crystals of ibrutinib with carboxylic acids
1 Jun 20
The present invention relates to co-crystals of ibrutinib and a pharmaceutical composition comprising the same as well as a method of preparing the same.
Wolfgang Albrecht, Jens Geier, Sebastian Rabe, David Perez Palacios
Filed: 27 Nov 18
Utility
Position-specific Asymmetric Deuterium Enriched Catecholamine Derivatives and Medicaments Comprising Said Compounds
27 May 20
Rudolf-Giesbert ALKEN, Frank Schneider
Filed: 15 Jul 19
Utility
S1P3 Antagonists
20 May 20
The present invention relates to antagonists of the S1P3 receptor formula (A) as herein described and pharmaceutical compositions thereof.
Chiara Caramelli, Cesare Federico, Emanuele Gabellieri, Matteo Magnani, Iolanda Micco, Georg C. Terstappen
Filed: 23 Jan 20
Utility
Methods of Treating Inflammatory Pain
13 May 20
The invention relates to an anti-CGRP antibody for use in the prevention and/or treatment of inflammatory pain and/or symptoms of inflammatory pain, and to a method of treating and/or preventing inflammatory pain and/or symptoms of inflammatory pain using an anti-CGRP antibody.
Kristian Todd Poulsen, David Louis Shelton, Joerg Zeller, Ian Machin, Laura Corradini
Filed: 3 Jun 19
Utility
Preventing, Treating, and Reducing (Persistent) Post-traumatic Headache
13 May 20
Disclosed herein are methods of treating or reducing incidence of post-traumatic headache and/or at least one secondary symptom associated with post-traumatic headache in a subject comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway.
Marcelo Bigal
Filed: 10 Jun 19
Utility
Sustained release olanzapine formulations
11 May 20
The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof.
Carine Claassen-Punt, Mark Alan Smith, Ling Chen, Ari Andrew Gershon
Filed: 19 Mar 18